WO2002070594A2 - A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge - Google Patents

A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge Download PDF

Info

Publication number
WO2002070594A2
WO2002070594A2 PCT/IB2002/001452 IB0201452W WO02070594A2 WO 2002070594 A2 WO2002070594 A2 WO 2002070594A2 IB 0201452 W IB0201452 W IB 0201452W WO 02070594 A2 WO02070594 A2 WO 02070594A2
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
sponge
foam
tendons
gel
Prior art date
Application number
PCT/IB2002/001452
Other languages
French (fr)
Other versions
WO2002070594A3 (en
WO2002070594A8 (en
Inventor
Alfred Schaufler
Original Assignee
Nycomed Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03006687A priority Critical patent/MXPA03006687A/en
Priority to AT02718481T priority patent/ATE310044T1/en
Priority to IL15709602A priority patent/IL157096A0/en
Priority to NZ527166A priority patent/NZ527166A/en
Priority to UA2003087939A priority patent/UA73028C2/en
Priority to EP02718481A priority patent/EP1368419B1/en
Priority to HU0303893A priority patent/HU228810B1/en
Priority to JP2002570628A priority patent/JP4104462B2/en
Priority to CA002435159A priority patent/CA2435159C/en
Priority to SI200230251T priority patent/SI1368419T1/en
Priority to BRPI0206705A priority patent/BRPI0206705B8/en
Priority to AU2002249528A priority patent/AU2002249528B2/en
Application filed by Nycomed Pharma As filed Critical Nycomed Pharma As
Priority to SK1036-2003A priority patent/SK287874B6/en
Priority to DE60207389T priority patent/DE60207389T2/en
Priority to KR1020037009893A priority patent/KR100847417B1/en
Priority to EEP200300349A priority patent/EE05587B1/en
Priority to EA200300821A priority patent/EA005697B1/en
Priority to DK02718481T priority patent/DK1368419T3/en
Publication of WO2002070594A2 publication Critical patent/WO2002070594A2/en
Publication of WO2002070594A3 publication Critical patent/WO2002070594A3/en
Priority to NO20033295A priority patent/NO332462B1/en
Priority to IL157096A priority patent/IL157096A/en
Priority to BG108122A priority patent/BG66343B1/en
Priority to HK04101070A priority patent/HK1058371A1/en
Publication of WO2002070594A8 publication Critical patent/WO2002070594A8/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/60Liquid-swellable gel-forming materials, e.g. super-absorbents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/36Surgical swabs, e.g. for absorbency or packing body cavities during surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/425Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/106Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/041Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/043Proteins; Polypeptides; Degradation products thereof
    • A61L31/044Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/043Proteins; Polypeptides; Degradation products thereof
    • A61L31/046Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08HDERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00Macromolecular products derived from proteins
    • C08H1/06Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00463Plasters use haemostatic
    • A61F2013/00472Plasters use haemostatic with chemical means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Definitions

  • the present invention relates to a method of preparing a collagen sponge.
  • the collagen sponge produced according to the invention is in particular useful in surgery primarily to stop capillary bleeding.
  • the collagen sponge may also be used as a carrier to be coated with a fibrin glue preparation.
  • the invention also relates to a device for extracting a part of a collagen foam.
  • the invention further relates to an elongated collagen sponge, primarily for gastrointestinal use.
  • Collagen has been used as a hemostyptic agent since the late sixties. Collagen is the most frequent structural protein in all mammalians. The monomeric protein of approximately 300 kDa (tropocollagen) is covalently crosslinked at specific sites. The mature protein is therefore insoluble and forms characteristic fibrils with high tensile strength. Numerous sub-classes of collagen have been described, the most common of which is collagen type I, the main collagen type in skin, tendons bones and cornea. Collagen is a fibrous protein consisting substantially of a triple helix with a length of approximately 290 nm. Five of these triple helices (tropocollagen molecules) are staggered to form a microfibril with a diameter of approximately 3.6 nm.
  • microfibrils have polar and non-polar segments that are readily accessible for specific inter- and intrafibrillar interactions.
  • Microfibrils are packed into a tetragonal lattice to form subfibrils with a diameter of about 30 nm. These subfibrils are then assembled into the collagen fibril, the basic unit of connective tissue, which has a diameter of several hundred nm and is therefore visible in a light microscope as a thin line, see reference 1.
  • Collagen gel and collagen sponge as produced during the manufacturing process, comprises these fibrils as the smallest units, as proved by microscopy.
  • Collagen may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue.
  • Fibrin glues i.e. the combination of fibrinogen, thrombin and aprotinin have successfully been used therapeutically for many years for gluing tissues and nerves and for sealing surfaces when there is minor bleeding.
  • One draw back of the fibrin glues has been that in case of major bleeding the glue is usually washed away before sufficient polymerisation of fibrin has occurred.
  • surgeons have manually applied liquid fibrin glues to absorbable carriers such as collagen fleece. Despite the impressive success of these combined applications this method has not been applied on a broad scale, due to some disadvantages.
  • the preparation is relatively cumbersome, the method requires experience and skilled personnel, and the preparation is not readily available in cases of emergency, the time for preparation being in the range of 10 to 15 min.
  • These factors stimulated the development of an improved product resulting in the development of a fixed combination of a collagen carrier covered with a coating of solid fibrinogen, solid thrombin and solid aprotinin as disclosed in EP 0 059 265.
  • the product disclosed in EP 0 059 265 which has been marketed under the trademark TachoComb ® can be applied directly to the wound. When the coating comes into contact with aqueous fluids like blood, other body fluids or saline, the components dissolve and fibrin is formed. The product is applied to the wound with a slight pressure and collagen is tightly bound (glued) to the injured surface. Haemostasis is achieved and the wound is sealed.
  • the function of collagen in TachoComb ® is mainly that of a carrier which adsorbs and confers mechanical stability to the coagulation preparation with which it is coated.
  • Other advantages of collagen, in particular in the form of a sponge, are its biodegradability, its relatively high tensile strength, even in the wet state, its high resistance against the penetration of liquids and air, and its high flexibility in the wet state.
  • the present invention is primarily concerned with the production of a collagen sponge which may be used as a carrier for fibrinogen, thrombin and/or aprotinin, e.g., as in TachoComb ® .
  • the collagen sponge may also be used directly, i.e. without a coating, as a bandage on topical injuries, for support of haemostasis, such as for prevention of rebleeding, for weak, diffuse bleeding from parenchymatic organs, for application on burns, skin grafts, decubitus or skin defects, or as a bandage on topical injuries.
  • WO 86/05811 discloses a weighted microsponge for immobilizing bioactive materials in motive bioreactor systems, the microsponge comprising a highly cross-linked collagen matrix.
  • the highly cross-linked collagen matrix is prepared by milling a source of Type I, II or III collagen to yield fibers having a diameter on the order of 1 to 50 ⁇ m and a length no greater than 200 ⁇ m.
  • the milled collagen is formed into a soluble collagen dissolved in a solvent, or an insoluble collagen dispersed in a solvent by admixture with a solvent, such as acetic acid, lactic acid, proprionic acid or butyric acid.
  • a collagen dispersion In the case of a collagen dispersion, the mixing is accomplished with a high level of agitation using a blender, so as to produce microfibers of the collagen.
  • a weighting additive is blended with the collagen-liquid mixture and the composite mixture is formed into small droplets and solidified by freezing.
  • a number of techniques for producing small particles are disclosed.
  • the frozen composite is vacuum freeze-dried, the combination of freezing and drying being referred to as lyophilization.
  • the freeze-dried collagen matrix composite is treated so as to cross-link the collagen.
  • the collagen can be cross-linked using either chemical cross-linking agents, by severe dehydration at an elevated temperature or by a combination.
  • the collagen matrix aimed at being resistant to collagenase and other enzymatic degradation thereby making these materials particularly suitable for culturing organisms.
  • the microsponges may be sterilized and aseptically packaged.
  • the collagen matrix has an open to the surface pore structure with an average pore size in the range of from about 1 to about 150 ⁇ m, the pores of the matrix occupying from about 70 to about 98% by volume of the microsponge.
  • the microsponge further has an average particle size of from about 100 to about 1000 ⁇ m and a specific gravity of above about 1.05.
  • the weighting material may be metal or alloys from metal, metal oxides and ceramics.
  • US 5,660,857 discloses a process for preparing a composite comprising an insoluble protein matrix and an oleaginous material, which is useful as a material for surgical dressings and biomedical implants, and as a cosmetic material for application to the skin.
  • the process of US 5,660,857 comprises the steps of mixing a protein, the oleaginous material and water to form an emulsion of the oleaginous material in an aqueous dispersion of the protein, and subsequently drying or freeze-drying the emulsion to form a film or a sponge.
  • the insoluble fibrous protein is predominantly comprised of insoluble collagen, which may suitably be obtained from bovine skin. In one embodiment, the collagen may be swollen in lactic acid prior to use.
  • WO 99/13902 discloses a method for producing a meningeal tissue growth matrix comprising the step of preparing physiologically compatible collagen which is substantially free of active viruses and prions.
  • the collagen is formed into a film, a sponge, a non-woven collagen or a felt.
  • the collagen is obtained by a process comprising cleaning skin, tendons, ligaments or bone of fat.
  • the material is then subjected to an enzyme treatment, whereby the collagen material is swelled.
  • the collagen material is then further swollen with an acid solution.
  • the collagen mixture is then homogenised.
  • the product obtained may be a matrix provided in the form of a collagen sponge, a non-woven matrix, felt or film, or a composite of two or more of he foregoing forms.
  • a collagen sponge can be provided by adaptation of the methods for forming collagen sponges disclosed in US 5,019,087.
  • the sponge can be prepared by lyophilization of a collagen dispersion prepared according to WO 99/13902.
  • the sponge density achieved is said to be about 0.1 mg/cm 3 to about 120 mg/cm 3 .
  • the pore size ranges from about 10 ⁇ m to • about 500 ⁇ m. Laminate type of collagen sponge and collagen film are mentioned.
  • US 5,618,551 relates to a non-crosslinked and potentially crosslinkable pepsintreated collagen or gelatin powder modified by oxidative cleavage in an aqueous solution, which is soluble at an acid pH and stable on storage at a temperature of below 0°C for at least one month.
  • the patent further relates to a process of preparing the powder, comprising preparing an acidic solution of pepsin-treated collagen, subjecting the acidic aqueous solution at room temperature to controlled oxidation, precipitating the oxidized and noncrosslinked pepsintreated collagen at an acid pH, and isolating, concentrating and dehydrating the noncrosslinked pepsintreated collaged so as to obtain it in the form of a reactive acidic powder, and freezing and storing the obtained reactive acidic powder at a temperature of below 0°C.
  • GB 1 292 326 discloses a method and apparatus for the preparation of collagen dispersions with a view to their applications, wherein a suspension of collagen fibres is prepared and subsequently introduced into a treatment chamber with stirring means. A sub-atmospheric pressure exists in the treatment chamber, in which the suspension is transformed into a dispersion by stirring and controlled acidification by means of a mineral or organic acid.
  • the preparation of spongy collagenic articles can be effected from dispersion or gels of collagen.
  • the documents refers to lyophilization and to dispersion or gels very rich in air bubbles.
  • GB 1 292 326 further mentions a problem of controlling the introduction or the elimination of air bubbles in a satisfactory manner.
  • the documents discloses, in two examples, a collagenic dispersion free of air bubbles with a collagen content of 2.5%, and an aerated dispersion of collagen with a collagen concentration of 2.5%, respectively.
  • the invention provides a method of preparing a collagen sponge, comprising the steps of: - preparing a collagen gel,
  • chamber diameter should be understood as the largest straight-line wall-to-wall distance in a chamber, i.e. as the largest diagonal straight-line distance of a chamber.
  • the chambers may be of a polygonal shape, such as of an octagonal shape.
  • the collagen gel has a dry mass in the range of 2-20 mg dry mass per 1 g gel, such as 4-18 mg, such as 5-13 mg, such as 6-11 mg per 1 g gel.
  • the dynamic viscosity of the collagen gel is preferably 2-20 Ncm, such as 4-10 Ncm, such as 6-8 Ncm.
  • the collagen sponge preferably has a water content of not more than 20%, such as 10-15%, such as about 18%.
  • the elasticity module of the collagen sponge is preferably in the range of 5-100 N/cm, such as 10-50 N/cm, and the density of the sponge is preferably 1-10 mg/cm 3 , such as 2-7 mg/cm 3 .
  • a collagen sponge prepared by the method according to the invention is air and liquid tight in the sense that, once the collagen sponge is applied to a wound, it will not allow air or liquid to pass through the collagen sponge. Liquids are absorbed in the sponge. This effect is primarily achieved due to the fact that the step of mixing air into the collagen gel provides a collagen sponge which has a three-dimensional structure with stacked chambers separated and substantially totally enclosed by walls of collagen material, in contradiction to those known collagen sponges which have a fibre structure.
  • the collagen gel may comprise material of different types, such as type I, II or III from mammalian, transgenic or recombinant sources, but all other types of collagen can be used.
  • the collagen may comprise material from tendons selected from the group consisting of equine tendons, human tendons, and bovine tendons.
  • the collagen gel may additionally or alternatively comprise recombinant collagen material.
  • the collagen content of the isolated parts of sponge is preferably 50% - 100% related to dry mass of the sponge, such as 75% - 100%, such as 80% - 100%, such as 85% - 100%, such as 90% - 100%, such as 92 - 100%, such as 92 - 98%, such as 93 - 97%, such as 94% - 96%.
  • the step of preparing the collagen gel preferably comprises the steps of:
  • the steps of storing, peeling, removing protein, reducing of germ content, and swelling aim at purifying the raw material, whereas the step of homogenising aims at obtaining the collagen in the form of a gel.
  • the step of reducing of germ content preferably comprises adding an acid, such as an organic acid, such as lactic acid to the tendons.
  • an organic solvent such as an alcohol, such as ethanol is preferably added to the tendons.
  • the step of swelling of the tendons preferably comprises adding lactic acid to the tendons.
  • the lactic acid used may be a 0.40 - 0.50% lactic acid, such as a 0.45% lactic acid.
  • the step of swelling of the tendons may comprise storing the tendons at a temperature of 4°C to 25°C, such as a temperature of 10°C to 20°C, for a period of 48 to 200 hours, such as a period of 100 to 200 hours.
  • the step of homogenising the swelled tendons is preferably carried out so as to obtain a particle size of collagen gel fragments, i.e. fibre balls, with a diameter of 0.8 - 1.2 cm, such as approximately 1 cm.
  • the physical characteristics of the collagen gel are preferably as stated above. The appropriate characteristics may for example be achieved by performing the step of homogenising the swelled tendons by means of a toothed disk mill or adequate homogenisation equipment.
  • the step of mixing air into the collagen gel preferably comprises the steps of:
  • At least some of the collagen gel separated from the collagen foam in the fractionising channel may be led back to the mixer.
  • the ratio between the amount of collagen gel which is led back to the mixer from the fractionising channel and the amount of fresh collagen gel led to the mixer is preferably between 0.1 and 0.5.
  • the step of separating collagen gel and collagen foam preferably comprises the steps of:
  • a temperature of 15°C to 40°C, such as 20°C to 20 25°C is maintained in the fractionising channel.
  • the collagen foam may be homogenised for a period of 2 to 4 minutes.
  • a neutraliser may be added to the collagen foam, and the collagen foam is preferably neutralised in order to arrive from a pH-value of, usually, between 2.5 and 3.5 to a pH-value in the collagen foam between 6.5 and 8.5.
  • a neutraliser comprising an ammonia solution may be used, and the collagen foam is preferably neutralised for a
  • the collagen foam Prior to the step of drying the collagen foam, the collagen foam is preferably filled into a drying container in such a way that substantially no air is drawn into the foam while filling.
  • the step of drying preferably comprises drying at a temperature between 15°C and 60°C, such as between 20° and 40°C, for a period of 50-200 hours, such as 100-150 hours, so as to obtain a dry collagen sponge.
  • the drying may be performed at a pressure slightly under atmospheric pressure, such as at a pressure of between 700 and 900 mbar, such as approximately 800 mbar.
  • the collagen sponge produced by the method according to the invention preferably fulfils at least one of the following criteria:
  • the step of isolating parts of collagen sponge may comprise dividing the collagen sponge into a plurality of parts by cutting.
  • the parts obtained may be shaped in any desirable form, such as conical, cylindrical, including cylindrical with an annular cross-section, rectangular, polygonal, cubic, and flat sheets or they may be transformed into a granulate by an appropriate granulating method etc.
  • the present invention relates to a method of preparing a collagen sponge, comprising the steps of:
  • - elasticity module in the range of 5 to 100 N/cm, - density in the range of 1 to 10 mg/cm 3 ,
  • the present invention provides a device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel, comprising:
  • fractionising channel comprising an inlet for receiving a flow of collagen foam, an outlet for a part of the flow of collagen foam, and a bottom portion which is inclined downwards in the direction of the flow of collagen foam
  • the present invention provides an elongated collagen sponge having a through-going hole or bore and a flexible wall.
  • a collagen sponge may be used closing wounds or re-establishing gastrointestinal funnel and trachea walls in mammalians.
  • the collagen sponge may have circular or elliptical cross- section.
  • the collagen sponge may be applied both as a filling, or as in a gastrointestinal funnel, or as an outer sleeve applied to an outer surface of a gastrointestinal funnel.
  • the inner diameter of the through-going hole or bore may, for application in various human gastrointestinal funnels and trachea, for example be as follows:
  • Oesophagus 0.5 - 2 cm
  • the collagen sponge may, e.g., be used for closing wounds after surgical removal of outpouchings on gastrointestinal funnel walls, such as after rectal surgery, such as after surgical removal of hemorrhoids.
  • Examples of indications made possible by the collagen sponge according to the invention are: - wound dressing,
  • haemostasis such as
  • Figs. 1 and 2 contain a flow chart illustrating the steps involved in a preferred embodiment of the method according to the invention
  • Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. réelle Erlangen, Germany), and
  • Fig. 4 discloses a stirring device for obtaining a measure of the viscosity of a collagen gel.
  • the invention comprises the following steps as illustrated in Figs. 1 and 2:
  • Step 1 Delivery of deep-frozen horse tendons
  • the horse tendons are delivered and stored at -18 °C to -25 °C.
  • the thin skin of the tendons is manually or mechanically removed with a knife.
  • the tendons are then again deep-frozen at -18 °C to -25 °C.
  • Step 3 Mechanical slicing of peeled horse tendons
  • peeled frozen tendons are disinfected for 30 min in 70 % ethanol and passed into production rooms under ethanol.
  • the tendons are then washed, and after washing the tendons are compacted to blocks and deep frozen at -18 °C to -25 °C.
  • the frozen tendon blocks are then sliced with a cutting machine with a rotating knife into slices having a thickness of approximately 1 mm.
  • Step 4 Washing and disinfection of the tendon slices
  • the tendon slices are first soaked in water for injection for 3 - 6 hours, then washed with water for injection or demineralized water or salt solutions containing Ca 2+ and/or Mg 2+ -ion within the range of 1-lOmM until the supernatant is free of hemoglobin.
  • the tendon slices are then disinfected in 70 % ethanol for 15 min and washed twice in 0.45 % lactic acid in drinking water (sterile filtered and depyrogenised) to remove the ethanol.
  • the washed tendon slices are soaked in 0.45 % lactic acid for 2-5 days, preferably 4 days, and then homogenised to a collagen gel. Exposure to 0.45 % lactic acid is considered to be one of the main virus inactivation steps.
  • the foam is dried in warm air in a high grade steel drying chamber for 48 - 150 hours, preferably 120 - 150 hours.
  • the result is collagen sponge shaped in blocks.
  • Blocks, also referred to as sheets, of collagen may for example be used as carriers for a coating.
  • the cutting is performed with a vertical cutting machine. First, the sides of the block are cut off to yield a block with vertical sides with a side length of 50 cm. This block is then cut vertically into 4 bars with a width of 11 cm. The bars are again trimmed at their upper and their lower side and then sliced into strips with dimensions of 50 x 11 x 0.4 - 0.7 cm.
  • the weight of the collagen sponge strips preferably takes into account any specification of collagen in the final product to be achieved, such as TachoComb ® H, TachoComb ® and Tachotop ® .
  • Step 9 Sorting the collagen sponge strips The collagen sponge strips are then subjected to a visual control. Strips with one or more of the following defects are discarded:
  • the sorted strips are stored for maximally 1 year in disinfected light metal containers at a temperature of 15 - 25 °C.
  • Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention, the photography being taken at a magnification factor of approximately 20,000 (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. réelle Er Weg, Germany).
  • the surface shown in the photography of Fig. 3 is a surface of a cross-sectional cut in a collagen sponge prepared by a method according to the present invention.
  • the dark areas in the photography represent chambers, while the light areas in the photography represent collagen material, including walls of collagen material separating the chambers.
  • Fig. 4 shows a stirring device for obtaining a measure of a viscosity of a liquid, comprising a container adapted to accommodate a liquid and means for stirring said liquid.
  • the stirring means comprise a rod attached to a fork shaped element.
  • a liquid in the container is stirred by applying a torque to the rod, resulting in a rotational movement of the fork shaped element.
  • the fork shaped element comprises a primary part 41 to which the rod is attached and a first and a second secondary part 42.
  • the secondary parts are attached to the ends of the primary part As the fork shaped element rotates the surfaces moves the liquid and thus stirs the liquid.
  • the device has the following dimensions.
  • the container is 110 mm high and 146 mm wide.
  • the rod is 220 mm high and has a diameter of 10 mm.
  • the primary part 41 of the fork is 90 mm long and 30 mm high.
  • the secondary parts 42 are 90 mm high and 30 mm wide. The distance from an outer edge of the secondary parts 42 to an inner surface of the container is 28 mm.
  • Table I below shows parameter values of three different cycles of the method according to the invention.
  • Table I Table II below shows parameter values of three different collagen sponges obtained by the method according to the invention.
  • This example relates to the indirect measurement of the viscosity of the collagen gel by torque measurement.
  • the equipment used for the torque measurement is: - Stirring machine: EUROSTAR POWER control-vise

Abstract

A method of preparing a collagen sponge comprises mixing air into a collagen gel, so as to obtain a collagen foam which is dried. From the dried product thereby obtained, collagen sponge is obtained by isolating parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or parts with an average chamber diagonal dimension of 3 mm. The collagen sponge may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue, such as a combination of fibrinogen, thrombin and aprotinin. A device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel is disclosed. An elongated collagen sponge having a through-going hole or bore and a flexible wall may be used for re-establishing walls in a mammalian gastrointestinal funnel or trachea system.

Description

A METHOD OF PREPARING A COLLAGEN SPONGE, A DEVICE FOR EXTRACTING A PART OF A COLLAGEN FOAM, AND AN ELONGATED COLLAGEN SPONGE
TECHNICAL FIELD
The present invention relates to a method of preparing a collagen sponge. The collagen sponge produced according to the invention is in particular useful in surgery primarily to stop capillary bleeding. The collagen sponge may also be used as a carrier to be coated with a fibrin glue preparation. The invention also relates to a device for extracting a part of a collagen foam. The invention further relates to an elongated collagen sponge, primarily for gastrointestinal use.
BACKGROUND OF THE INVENTION
Collagen has been used as a hemostyptic agent since the late sixties. Collagen is the most frequent structural protein in all mammalians. The monomeric protein of approximately 300 kDa (tropocollagen) is covalently crosslinked at specific sites. The mature protein is therefore insoluble and forms characteristic fibrils with high tensile strength. Numerous sub-classes of collagen have been described, the most common of which is collagen type I, the main collagen type in skin, tendons bones and cornea. Collagen is a fibrous protein consisting substantially of a triple helix with a length of approximately 290 nm. Five of these triple helices (tropocollagen molecules) are staggered to form a microfibril with a diameter of approximately 3.6 nm. These microfibrils have polar and non-polar segments that are readily accessible for specific inter- and intrafibrillar interactions. Microfibrils are packed into a tetragonal lattice to form subfibrils with a diameter of about 30 nm. These subfibrils are then assembled into the collagen fibril, the basic unit of connective tissue, which has a diameter of several hundred nm and is therefore visible in a light microscope as a thin line, see reference 1. Collagen gel and collagen sponge, as produced during the manufacturing process, comprises these fibrils as the smallest units, as proved by microscopy.
Collagen may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue. Fibrin glues i.e. the combination of fibrinogen, thrombin and aprotinin have successfully been used therapeutically for many years for gluing tissues and nerves and for sealing surfaces when there is minor bleeding. One draw back of the fibrin glues has been that in case of major bleeding the glue is usually washed away before sufficient polymerisation of fibrin has occurred. To overcome this problem surgeons have manually applied liquid fibrin glues to absorbable carriers such as collagen fleece. Despite the impressive success of these combined applications this method has not been applied on a broad scale, due to some disadvantages. The preparation is relatively cumbersome, the method requires experience and skilled personnel, and the preparation is not readily available in cases of emergency, the time for preparation being in the range of 10 to 15 min. These factors stimulated the development of an improved product resulting in the development of a fixed combination of a collagen carrier covered with a coating of solid fibrinogen, solid thrombin and solid aprotinin as disclosed in EP 0 059 265. The product disclosed in EP 0 059 265 which has been marketed under the trademark TachoComb® can be applied directly to the wound. When the coating comes into contact with aqueous fluids like blood, other body fluids or saline, the components dissolve and fibrin is formed. The product is applied to the wound with a slight pressure and collagen is tightly bound (glued) to the injured surface. Haemostasis is achieved and the wound is sealed.
Beside some blood coagulation stimulating activity, the function of collagen in TachoComb® is mainly that of a carrier which adsorbs and confers mechanical stability to the coagulation preparation with which it is coated. Other advantages of collagen, in particular in the form of a sponge, are its biodegradability, its relatively high tensile strength, even in the wet state, its high resistance against the penetration of liquids and air, and its high flexibility in the wet state.
The present invention is primarily concerned with the production of a collagen sponge which may be used as a carrier for fibrinogen, thrombin and/or aprotinin, e.g., as in TachoComb®. The collagen sponge may also be used directly, i.e. without a coating, as a bandage on topical injuries, for support of haemostasis, such as for prevention of rebleeding, for weak, diffuse bleeding from parenchymatic organs, for application on burns, skin grafts, decubitus or skin defects, or as a bandage on topical injuries.
In the prior art, a number of methods for preparing a collagen carrier have been suggested. WO 86/05811 discloses a weighted microsponge for immobilizing bioactive materials in motive bioreactor systems, the microsponge comprising a highly cross-linked collagen matrix. The highly cross-linked collagen matrix is prepared by milling a source of Type I, II or III collagen to yield fibers having a diameter on the order of 1 to 50 μm and a length no greater than 200 μm. The milled collagen is formed into a soluble collagen dissolved in a solvent, or an insoluble collagen dispersed in a solvent by admixture with a solvent, such as acetic acid, lactic acid, proprionic acid or butyric acid. In the case of a collagen dispersion, the mixing is accomplished with a high level of agitation using a blender, so as to produce microfibers of the collagen. Next, a weighting additive is blended with the collagen-liquid mixture and the composite mixture is formed into small droplets and solidified by freezing. A number of techniques for producing small particles are disclosed. The frozen composite is vacuum freeze-dried, the combination of freezing and drying being referred to as lyophilization. The freeze-dried collagen matrix composite is treated so as to cross-link the collagen. The collagen can be cross-linked using either chemical cross-linking agents, by severe dehydration at an elevated temperature or by a combination. The collagen matrix aimed at being resistant to collagenase and other enzymatic degradation thereby making these materials particularly suitable for culturing organisms. After washing the cross-linked collagen matrix, the microsponges may be sterilized and aseptically packaged. In the weighted microsponge, the collagen matrix has an open to the surface pore structure with an average pore size in the range of from about 1 to about 150 μm, the pores of the matrix occupying from about 70 to about 98% by volume of the microsponge. The microsponge further has an average particle size of from about 100 to about 1000 μm and a specific gravity of above about 1.05. The weighting material may be metal or alloys from metal, metal oxides and ceramics.
US 5,660,857 discloses a process for preparing a composite comprising an insoluble protein matrix and an oleaginous material, which is useful as a material for surgical dressings and biomedical implants, and as a cosmetic material for application to the skin. The process of US 5,660,857 comprises the steps of mixing a protein, the oleaginous material and water to form an emulsion of the oleaginous material in an aqueous dispersion of the protein, and subsequently drying or freeze-drying the emulsion to form a film or a sponge. The insoluble fibrous protein is predominantly comprised of insoluble collagen, which may suitably be obtained from bovine skin. In one embodiment, the collagen may be swollen in lactic acid prior to use.
WO 99/13902 discloses a method for producing a meningeal tissue growth matrix comprising the step of preparing physiologically compatible collagen which is substantially free of active viruses and prions. The collagen is formed into a film, a sponge, a non-woven collagen or a felt. The collagen is obtained by a process comprising cleaning skin, tendons, ligaments or bone of fat. The material is then subjected to an enzyme treatment, whereby the collagen material is swelled. The collagen material is then further swollen with an acid solution. The collagen mixture is then homogenised. The product obtained may be a matrix provided in the form of a collagen sponge, a non-woven matrix, felt or film, or a composite of two or more of he foregoing forms. A collagen sponge can be provided by adaptation of the methods for forming collagen sponges disclosed in US 5,019,087. The sponge can be prepared by lyophilization of a collagen dispersion prepared according to WO 99/13902. The sponge density achieved is said to be about 0.1 mg/cm3 to about 120 mg/cm3. According to the disclosure of WO 99/13902, the pore size ranges from about 10 μm to • about 500 μm. Laminate type of collagen sponge and collagen film are mentioned. US 5,618,551 relates to a non-crosslinked and potentially crosslinkable pepsintreated collagen or gelatin powder modified by oxidative cleavage in an aqueous solution, which is soluble at an acid pH and stable on storage at a temperature of below 0°C for at least one month. The patent further relates to a process of preparing the powder, comprising preparing an acidic solution of pepsin-treated collagen, subjecting the acidic aqueous solution at room temperature to controlled oxidation, precipitating the oxidized and noncrosslinked pepsintreated collagen at an acid pH, and isolating, concentrating and dehydrating the noncrosslinked pepsintreated collaged so as to obtain it in the form of a reactive acidic powder, and freezing and storing the obtained reactive acidic powder at a temperature of below 0°C.
GB 1 292 326 discloses a method and apparatus for the preparation of collagen dispersions with a view to their applications, wherein a suspension of collagen fibres is prepared and subsequently introduced into a treatment chamber with stirring means. A sub-atmospheric pressure exists in the treatment chamber, in which the suspension is transformed into a dispersion by stirring and controlled acidification by means of a mineral or organic acid. According to the disclosure of GB 1 292 326, the preparation of spongy collagenic articles can be effected from dispersion or gels of collagen. In this context the documents refers to lyophilization and to dispersion or gels very rich in air bubbles. GB 1 292 326 further mentions a problem of controlling the introduction or the elimination of air bubbles in a satisfactory manner. The documents discloses, in two examples, a collagenic dispersion free of air bubbles with a collagen content of 2.5%, and an aerated dispersion of collagen with a collagen concentration of 2.5%, respectively.
Chemical Abstracts, Columbus Ohio, US, Vol. 98 13 June 1983 No. 24 mentions a collagen obtained from animal tissues such as skin or tendon bone which has been submitted to acid treatment. The collagen is reaggregated by dialysis, during which process a net of highly birefringent crystal fibres is formed. The collagen can be shaped into 0.5 mm - 2 cm sheets, or be mixed with air to form sponges, or be dispersed as a cream.
DESCRIPTION OF THE INVENTION
It has been found that the successful coating of a collagen sponge with a fibrin glue preparation depends on the texture of the collagen sponge. It is thus an object of the present invention to provide a method of producing a collagen sponge with a certain texture, in particular with the aim of making the collagen sponge suitable for coating with a fibrin glue preparation, so as to obtain a material for healing and sealing wounds. It is a further object of the invention to provide a method of producing a collagen sponge having improved physical characteristics in relation to prior art sponges, in the sense of improved humidity, elasticity, density and elasticity module. It is a further object of the invention to provide a method for preparing a collagen sponge which is air and liquid tight in the sense that, once the collagen sponge is applied to a wound, it will not allow air or liquid to soak through the collagen sponge. It is a still further object of the invention to provide a wound closing material which can be used in gastrointestinal funnels or trachea.
Thus, in a first aspect the invention provides a method of preparing a collagen sponge, comprising the steps of: - preparing a collagen gel,
- mixing air into the collagen gel, so as to obtain a collagen foam,
- drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or having a chamber diameter average of at most 3 mm.
In the present context, the term "chamber diameter" should be understood as the largest straight-line wall-to-wall distance in a chamber, i.e. as the largest diagonal straight-line distance of a chamber. The chambers may be of a polygonal shape, such as of an octagonal shape.
It has been found that a chamber diameter of more than 0J5 mm and less than 4 mm, or a chamber diameter average of at most 3 mm, renders the collagen sponge particularly useful for being coated with a fibrin glue preparation. Preferably, the collagen gel has a dry mass in the range of 2-20 mg dry mass per 1 g gel, such as 4-18 mg, such as 5-13 mg, such as 6-11 mg per 1 g gel. The dynamic viscosity of the collagen gel is preferably 2-20 Ncm, such as 4-10 Ncm, such as 6-8 Ncm. The collagen sponge preferably has a water content of not more than 20%, such as 10-15%, such as about 18%. The elasticity module of the collagen sponge is preferably in the range of 5-100 N/cm, such as 10-50 N/cm, and the density of the sponge is preferably 1-10 mg/cm3, such as 2-7 mg/cm3.
It has been found that a collagen sponge prepared by the method according to the invention is air and liquid tight in the sense that, once the collagen sponge is applied to a wound, it will not allow air or liquid to pass through the collagen sponge. Liquids are absorbed in the sponge. This effect is primarily achieved due to the fact that the step of mixing air into the collagen gel provides a collagen sponge which has a three-dimensional structure with stacked chambers separated and substantially totally enclosed by walls of collagen material, in contradiction to those known collagen sponges which have a fibre structure.
The collagen gel may comprise material of different types, such as type I, II or III from mammalian, transgenic or recombinant sources, but all other types of collagen can be used. The collagen may comprise material from tendons selected from the group consisting of equine tendons, human tendons, and bovine tendons. The collagen gel may additionally or alternatively comprise recombinant collagen material.
The collagen content of the isolated parts of sponge is preferably 50% - 100% related to dry mass of the sponge, such as 75% - 100%, such as 80% - 100%, such as 85% - 100%, such as 90% - 100%, such as 92 - 100%, such as 92 - 98%, such as 93 - 97%, such as 94% - 96%.
The step of preparing the collagen gel preferably comprises the steps of:
- storing the tendons at a temperature between -10°C and -30°C, and peeling the tendons,
- removing foreign protein from the tendons,
- reducing germ content in the tendons, - swelling the tendons,
- homogenising the swelled tendons.
The steps of storing, peeling, removing protein, reducing of germ content, and swelling aim at purifying the raw material, whereas the step of homogenising aims at obtaining the collagen in the form of a gel.
The step of reducing of germ content preferably comprises adding an acid, such as an organic acid, such as lactic acid to the tendons. Further, an organic solvent, such as an alcohol, such as ethanol is preferably added to the tendons. Further, the step of swelling of the tendons preferably comprises adding lactic acid to the tendons. The lactic acid used may be a 0.40 - 0.50% lactic acid, such as a 0.45% lactic acid.
The step of swelling of the tendons may comprise storing the tendons at a temperature of 4°C to 25°C, such as a temperature of 10°C to 20°C, for a period of 48 to 200 hours, such as a period of 100 to 200 hours.
The step of homogenising the swelled tendons is preferably carried out so as to obtain a particle size of collagen gel fragments, i.e. fibre balls, with a diameter of 0.8 - 1.2 cm, such as approximately 1 cm. Further, the physical characteristics of the collagen gel are preferably as stated above. The appropriate characteristics may for example be achieved by performing the step of homogenising the swelled tendons by means of a toothed disk mill or adequate homogenisation equipment.
5 The step of mixing air into the collagen gel preferably comprises the steps of:
- mixing ambient air into the gel by means of a mixer so as to generate a collagen foam,
- feeding the mixed gel foam into a fractionising channel,
- separating collagen gel and collagen foam contained in the fractionising channel.
10 At least some of the collagen gel separated from the collagen foam in the fractionising channel may be led back to the mixer. In that case, the ratio between the amount of collagen gel which is led back to the mixer from the fractionising channel and the amount of fresh collagen gel led to the mixer is preferably between 0.1 and 0.5. The step of separating collagen gel and collagen foam preferably comprises the steps of:
15 - separating a selected part of the collagen foam contained in the fractionising channel,
- leading the selected part of the collagen foam out of the fractionising channel for drying thereof.
In a preferred embodiment of the method, a temperature of 15°C to 40°C, such as 20°C to 20 25°C is maintained in the fractionising channel.
Subsequent to mixing air into the collagen gel, the collagen foam may be homogenised for a period of 2 to 4 minutes.
25 Prior to the step of drying the collagen foam and subsequent to the step of mixing air into the collagen get, a neutraliser may be added to the collagen foam, and the collagen foam is preferably neutralised in order to arrive from a pH-value of, usually, between 2.5 and 3.5 to a pH-value in the collagen foam between 6.5 and 8.5. A neutraliser comprising an ammonia solution may be used, and the collagen foam is preferably neutralised for a
30 period of 5-30 hours, such as 10-20 hours, such as approximately 24 hours.
Prior to the step of drying the collagen foam, the collagen foam is preferably filled into a drying container in such a way that substantially no air is drawn into the foam while filling.
35 The step of drying preferably comprises drying at a temperature between 15°C and 60°C, such as between 20° and 40°C, for a period of 50-200 hours, such as 100-150 hours, so as to obtain a dry collagen sponge. The drying may be performed at a pressure slightly under atmospheric pressure, such as at a pressure of between 700 and 900 mbar, such as approximately 800 mbar. The collagen sponge produced by the method according to the invention preferably fulfils at least one of the following criteria:
- pH-value between 5.0 and 6.0, - lactic acid content at the most 5%,
- ammonium content at the most 0.5%,
- soluble protein content, calculated as albumin content, at the most 0.5%,
- sulphate ashes content at the most 1.0%,
- heavy metal content at the most 20 ppm, - microbiological purity, at the most 103 CFU/g,
- collagen content of 75% to 100%,
- density of 1-10 mg/cm3, such as 2-7 mg/cm3,
- elasticity module of 5-100 N/cm, such as 10-50 N/cm.
The step of isolating parts of collagen sponge may comprise dividing the collagen sponge into a plurality of parts by cutting. The parts obtained may be shaped in any desirable form, such as conical, cylindrical, including cylindrical with an annular cross-section, rectangular, polygonal, cubic, and flat sheets or they may be transformed into a granulate by an appropriate granulating method etc.
In a second aspect, the present invention relates to a method of preparing a collagen sponge, comprising the steps of:
- preparing a collagen gel,
- mixing air into the collagen gel, so as to obtain a collagen foam, - drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge having the following properties:
- elasticity module in the range of 5 to 100 N/cm, - density in the range of 1 to 10 mg/cm3,
- chamber diameter of more than 0J5 mm and less than 4 mm, or a chamber diameter average of at most 3 mm.
It should be understood that any and all steps of the method according to the first aspect of the invention may also be performed in the method according to the second aspect of the invention. Further, any and all characteristics and features of the collagen sponge produced by the method according to the first aspect of the invention may also be achieved by the method according to the second aspect of the invention. In a third aspect, the present invention provides a device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel, comprising:
- a fractionising channel comprising an inlet for receiving a flow of collagen foam, an outlet for a part of the flow of collagen foam, and a bottom portion which is inclined downwards in the direction of the flow of collagen foam,
- at least one outlet for collagen gel at the bottom portion of the fractionising channel, wherein the position of the outlet is movable in a vertical direction at an end of the fractionising channel.
In a fourth aspect, the present invention provides an elongated collagen sponge having a through-going hole or bore and a flexible wall. In a preferred embodiment, such a collagen sponge may be used closing wounds or re-establishing gastrointestinal funnel and trachea walls in mammalians. Thus, the collagen sponge may have circular or elliptical cross- section. The collagen sponge may be applied both as a filling, or as in a gastrointestinal funnel, or as an outer sleeve applied to an outer surface of a gastrointestinal funnel.
The inner diameter of the through-going hole or bore may, for application in various human gastrointestinal funnels and trachea, for example be as follows:
Bowels: 0.5 - 6 cm Rectum: 1 - 4 cm
Large intestine: 2 - 6 cm
Small intestine: 0.5 - 3 cm
Oesophagus: 0.5 - 2 cm
Trachea : 1 - 4 cm
The collagen sponge may, e.g., be used for closing wounds after surgical removal of outpouchings on gastrointestinal funnel walls, such as after rectal surgery, such as after surgical removal of hemorrhoids. Examples of indications made possible by the collagen sponge according to the invention are: - wound dressing,
- support of haemostasis, such as
- weak, diffuse bleeding from parenchymatic organs,
- surgical procedures on surgery locations where ectrosurgery or ligation has been performed prior to application of the collagen sponge, - prevention of rebleeding (securing of sutures),
- application on burns,
- bandage on topical injuries,
- drug delivery, such as delivery of antibiotics. BRIEF DESCRIPTION OF THE DRAWINGS
Figs. 1 and 2 contain a flow chart illustrating the steps involved in a preferred embodiment of the method according to the invention,
Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. Klinik Erlangen, Germany), and
Fig. 4 discloses a stirring device for obtaining a measure of the viscosity of a collagen gel.
DESCRIPTION OF THE DRAWINGS
In a preferred embodiment, the invention comprises the following steps as illustrated in Figs. 1 and 2:
Step 1 Delivery of deep-frozen horse tendons
The horse tendons are delivered and stored at -18 °C to -25 °C.
Step 2 Peeling of horse tendons
In a half-frozen state, the thin skin of the tendons is manually or mechanically removed with a knife. The tendons are then again deep-frozen at -18 °C to -25 °C.
Step 3 Mechanical slicing of peeled horse tendons
Optionally, peeled frozen tendons are disinfected for 30 min in 70 % ethanol and passed into production rooms under ethanol. The tendons are then washed, and after washing the tendons are compacted to blocks and deep frozen at -18 °C to -25 °C. The frozen tendon blocks are then sliced with a cutting machine with a rotating knife into slices having a thickness of approximately 1 mm.
Step 4 Washing and disinfection of the tendon slices
In order to remove soluble proteins, the tendon slices are first soaked in water for injection for 3 - 6 hours, then washed with water for injection or demineralized water or salt solutions containing Ca2+ and/or Mg2+-ion within the range of 1-lOmM until the supernatant is free of hemoglobin. The tendon slices are then disinfected in 70 % ethanol for 15 min and washed twice in 0.45 % lactic acid in drinking water (sterile filtered and depyrogenised) to remove the ethanol.
Step 5 Production of collagen pel
The washed tendon slices are soaked in 0.45 % lactic acid for 2-5 days, preferably 4 days, and then homogenised to a collagen gel. Exposure to 0.45 % lactic acid is considered to be one of the main virus inactivation steps.
Step 6 Foaming
With dissolver stirrers sterile filtered air is whipped into the collagen gel. The arising foam is fractioned, and the fraction with a bubble size of 1 - 3 mm is collected. The foam is poured from the steel container into a barrel which is slowly rotated for approximately 3 minutes to obtain a homogeneous foam. This foam is filled into drying containers. The base of the container consists of a textile tissue which is permeable to fluids, so as to allow draining of the foam. After 5 - 24 hours, preferably 18-24 hours, the drained foam is exposed to ammonia gas e.g generated from a 26 % ammonia solution of DAB quality. During this process, the surplus of ammonia shifts the pH of the foam to the alkaline region. Ammonia is removed during the subsequent drying process resulting in a neutral product.
Step 7 Drying the foam
The foam is dried in warm air in a high grade steel drying chamber for 48 - 150 hours, preferably 120 - 150 hours. The result is collagen sponge shaped in blocks.
Step 8 Cutting the collagen blocks
Blocks, also referred to as sheets, of collagen may for example be used as carriers for a coating. The cutting is performed with a vertical cutting machine. First, the sides of the block are cut off to yield a block with vertical sides with a side length of 50 cm. This block is then cut vertically into 4 bars with a width of 11 cm. The bars are again trimmed at their upper and their lower side and then sliced into strips with dimensions of 50 x 11 x 0.4 - 0.7 cm. The weight of the collagen sponge strips preferably takes into account any specification of collagen in the final product to be achieved, such as TachoComb® H, TachoComb® and Tachotop®.
Step 9 Sorting the collagen sponge strips The collagen sponge strips are then subjected to a visual control. Strips with one or more of the following defects are discarded:
- strips with an average chamber diameter smaller than 1 mm or larger than 3 mm
- strips with inhomogeneous chamber structure - strips with holes (single chambers with a depth larger than the thickness of the sponge)
The sorted strips are stored for maximally 1 year in disinfected light metal containers at a temperature of 15 - 25 °C.
Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention, the photography being taken at a magnification factor of approximately 20,000 (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. Klinik Erlangen, Germany). The surface shown in the photography of Fig. 3 is a surface of a cross-sectional cut in a collagen sponge prepared by a method according to the present invention. The dark areas in the photography represent chambers, while the light areas in the photography represent collagen material, including walls of collagen material separating the chambers.
Fig. 4 shows a stirring device for obtaining a measure of a viscosity of a liquid, comprising a container adapted to accommodate a liquid and means for stirring said liquid. The stirring means comprise a rod attached to a fork shaped element. A liquid in the container is stirred by applying a torque to the rod, resulting in a rotational movement of the fork shaped element. The fork shaped element comprises a primary part 41 to which the rod is attached and a first and a second secondary part 42. The secondary parts are attached to the ends of the primary part As the fork shaped element rotates the surfaces moves the liquid and thus stirs the liquid.
In one embodiment the device has the following dimensions. The container is 110 mm high and 146 mm wide. The rod is 220 mm high and has a diameter of 10 mm. The primary part 41 of the fork is 90 mm long and 30 mm high. The secondary parts 42 are 90 mm high and 30 mm wide. The distance from an outer edge of the secondary parts 42 to an inner surface of the container is 28 mm.
Example I
Table I below shows parameter values of three different cycles of the method according to the invention.
Figure imgf000015_0001
Table I Table II below shows parameter values of three different collagen sponges obtained by the method according to the invention.
Figure imgf000016_0001
Table II
Example II
This example relates to the indirect measurement of the viscosity of the collagen gel by torque measurement.
The equipment used for the torque measurement is: - Stirring machine: EUROSTAR POWER control-vise
- Windows-Software: IKASOFT dc
- Torque indicator: VISCOKLICK VK 1
- Datalogger DC 2 - Special stirrer construction ("fork") with defined dimensions, cf. Fig. 4
- Funnel with an inner diameter of 14.6 cm and a height of 20.5 cm
- Thermometer
- Balance
An amount of 1500 g of collagen gel is filled into the funnel. The temperature of the sample is 23°C. The "fork" stirrer is fixed in the centre of the funnel. Then measurement is started. The Torque indicator is transforming the resistance of the stirrer into a value (Ncm) representing the dynamic gel viscosity.
In order to verify the measurement of the torque, a standard solution of 59% Polyethylenglycol is prepared. Viscosity of this solution is measured by a Haake Visosimeter RV 20 Rotovisko. The dynamical viscosity η of this solution is in the range of η = 925 ± 25 mPas at 23°C. This solution viscosity is measured by the above gel measuring equipment, and the torque value thereby measured should be in the range of 3.66 Ncm ± 5% at 23°C.
REFERENCES
1. Baer, E. Gathercole, L.J. and Keller, A., Structure hierarchies in tendon collagen: an interim summary, Proc. Colston Conf., 1974, 189; Hiltner, A. Cassidy, J.J. and Baer, E., Mechanical properties of biological polymers, Ann. Rev. Mater. Sci., 15, 455, 1985)

Claims

1. A method of preparing a collagen sponge, comprising the steps of:
- preparing a collagen gel, - mixing air into the collagen gel, so as to obtain a collagen foam,
- drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or parts with an average chamber diagonal dimension of 3 mm.
2. A method according to claim 1, wherein the collagen content of the isolated parts of sponge is 50 to 100%.
3. A method according to claim 2 or 3, wherein the collagen gel comprises collagen material of different types from at least one of the following sources: mammalian, transgenic and recombinant sources.
4. A method according to claim 3, wherein the collagen comprises material from tendons selected from the group consisting of equine tendons, bovine tendons and human tendons.
5. A method according to claim 3 or 4, wherein the step of preparing the collagen gel comprises the steps of:
- storing the tendons at a temperature between -10°C and -30°C, and peeling the tendons,
- removing foreign protein from the tendons,
- reducing germ content in the tendons,
- swelling the tendons,
- homogenising the swelled tendons.
6. A method according to claim 5, wherein the step of reducing germ content comprises adding an acid and an organic solvent to the tendons.
7. A method according to claim 6, wherein acid is an organic acid, such as lactic acid.
8. A method according to claim 6 or 7, wherein the organic solvent is an alcohol, such as ethanol.
9. A method according to any of claims 5-8, wherein the step of swelling the tendons comprises adding lactic acid to the tendons.
10. A method according to any of claims 5-9, wherein the acid has a pH value in the range 5 of 1 to 4, such as 1.5 to 3.5, such as 2.5 to 3.0.
11. A method according to any of claims 5-10, wherein the lactic acid is a 0.45% lactic acid.
10 12. A method according to any of claims 5-11, wherein the step of swelling the tendons comprises storing the tendons at a temperature of 4°C to 25°C for a period of 48 to 200 hours.
13. A method according to claim 12, wherein the tendons are stored for a period of 100 to 15 120 hours.
14. A method according to any of claims 5-13, wherein the step of homogenising the swelled tendons comprises obtaining a substance comprising particles of tendons, the particles having a length or diameter of 0.8 to 1.2 cm.
20
15. A method according to any of claims 5-14, wherein the step of homogenising the swelled tendons comprises obtaining a substance having a viscosity of 2 to 20 Ncm.
16. A method according to any of claims 5-15, wherein the step of homogenising the 5 swelled tendons is carried out by means of a toothed disk mill or comparable equipment
17. A method according to any of the preceding claims, wherein the collagen gel has a dynamic viscosity of 2-20 Ncm.
0 18. A method according to any of the preceding claims, wherein the step of mixing air into the collagen gel comprises the steps of:
- mixing ambient air into the gel by means of a mixer so as to generate a collagen foam,
- feeding the mixed gel foam into a fractionising channel,
- separating collagen gel and collagen foam contained in the fractionising channel. 5
19. A method according to claim 18, wherein at least some of the collagen gel separated from the collagen foam in the fractionising channel is led back to the mixer.
20. A method according to claim 19, wherein the ratio between the amount of collagen gel which is led back to the mixer from the fractionising channel and the amount of fresh collagen gel led to the mixer is between 0.1 and 0.5.
21. A method according to any of claims 18-20, wherein the step of separating collagen gel and collagen foam comprises the steps of:
- separating a selected part of the collagen foam contained in the fractionising channel,
- leading the selected part of the collagen foam out of the fractionising channel for drying thereof.
22. A method according to any of claims 18-21, further comprising maintaining a temperature between 15°C and 40°C in the fractionising channel.
23. A method according to any of the preceding claims, further comprising, subsequent to mixing air into the collagen gel, homogenising the collagen foam for a period of 2 to 4 minutes.
24. A method according to any of the preceding claims, further comprising, prior to the step of drying the collagen foam and subsequent to the step of mixing air into the collagen gel, adding a neutraliser to the collagen foam and neutralising the collagen foam in order to achieve a pH-value in the collagen foam between 6.5 and 8.5.
25. A method according to claim 24, wherein the neutraliser comprises an ammonia solution.
26. A method according to claim 24 or 25, wherein the collagen foam is neutralised for a period of 5-30 hours.
27. A method according to claim 26, wherein the collagen foam is neutralised for a period of 20-30 hours.
28. A method according to any of the preceding claims, wherein the step of drying comprises drying at a temperature between 15°C and 60°C for a period of 48-200 hours, so as to obtain a dry collagen sponge.
29. A method according to claim 28, wherein the step of drying is carried out at a pressure of 700 to 900 mbar.
30. A method according to any of the preceding claims, wherein the step of drying comprises drying at a temperature between 15°C and 40°C for a period of 100-200 hours.
31. A method according to any of the preceding claims, wherein the collagen sponge fulfils 5 at least one of the following criteria:
- pH-value between 5.0 and 6.0,
- lactic acid content at the most 5%,
- ammonium content at the most 0.5%,
- soluble protein content, calculated as albumin content, at the most 0.5%, 10 - sulphate ashes content at the most 1.0%,
- heavy metal content at the most 20 ppm,
- microbiological purity, at the most 103 CFU/g,
- collagen content of 75 to 100%,
- density of 1 to 10 mg/cm3,
15 - elasticity module in the range of 5-100 N/cm.
32. A method according to any of the preceding claims, wherein the collagen sponge has a water content of not more than 20%.
20 33. A method according to any of the preceding claims, wherein the step of isolating parts of collagen sponge comprises dividing the collagen sponge into a plurality of parts by cutting.
34. A method of preparing a collagen sponge, comprising the steps of: 25 - preparing a collagen gel,
- mixing air into the collagen gel, so as to obtain a collagen foam,
- drying the collagen foam, so as to obtain a dry block of collagen sponge having chambers therein,
- isolating, from the block of collagen sponge, parts of sponge having the following 0 properties:
- elasticity module in the range of 5 to 100 N/cm,
- density in the range of 1 to 10 mg/cm3,
- chamber diameter of more than 0.75 mm and less than 4 mm, or a chamber diameter average of at most 3 mm. 5
35. A method according to claim 34, comprising the steps of any of claims 1-33.
36. A device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel, comprising: - a fractionising channel comprising an inlet for receiving a flow of collagen foam, an outlet for a part of the flow of collagen foam, and a bottom portion which is inclined downwards in the direction of the flow of collagen foam,
- at least one outlet for collagen gel at the bottom portion of the fractionising channel, 5 wherein the position of the outlet is movable in a vertical direction at an end of the fractionising channel.
37. An elongated collagen sponge having a through-going hole or bore and a flexible wall.
10 38. An elongated collagen sponge according to claim 37 and having a circular or elliptical cross-section.
39. An elongated collagen sponge according to claim 37 or 38, and having outer dimensions allowing the sponge to be used for closing wounds or re-establishing walls in a
15 mammalian gastrointestinal funnel or trachea system.
40. An elongated collagen sponge according to any of claims 37-39, wherein the bore or hole has diagonal dimensions corresponding to the inner or outer cross-sectional dimensions of mammalian gastrointestinal funnels or tracheas. 0
41. An elongated collagen sponge according to claim 39 or 40 having outer dimensions corresponding to the inner dimension of the human rectum, so as to make the sponge suitable for closing wounds in the rectum wall or re-establishing the rectum wall.
PCT/IB2002/001452 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge WO2002070594A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SK1036-2003A SK287874B6 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and en elongated collagen sponge
AT02718481T ATE310044T1 (en) 2001-01-25 2002-01-25 METHOD FOR PRODUCING A COLLAGEN SPONGE; EXTRACTION DEVICE OF PART OF A COLLAGEN SPONGE AND EXTENDED COLLAGEN SPONGE
DE60207389T DE60207389T2 (en) 2001-01-25 2002-01-25 METHOD FOR PRODUCING A COLLAGEN SPONGE; EXTRACTION DEVICE OF A PART OF A COLLAGEN SPONGE AND EXTENDED COLLAGEN SPONGE
UA2003087939A UA73028C2 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge (variants), a device for extracting a part of a collagen foam and an elongated collagen sponge
EP02718481A EP1368419B1 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
HU0303893A HU228810B1 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
JP2002570628A JP4104462B2 (en) 2001-01-25 2002-01-25 Method for preparing collagen sponge, apparatus for extracting part of collagen foam, and elongated collagen sponge
CA002435159A CA2435159C (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge
SI200230251T SI1368419T1 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
BRPI0206705A BRPI0206705B8 (en) 2001-01-25 2002-01-25 method for preparing a collagen sponge.
AU2002249528A AU2002249528B2 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
MXPA03006687A MXPA03006687A (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge.
IL15709602A IL157096A0 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
NZ527166A NZ527166A (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
KR1020037009893A KR100847417B1 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
EEP200300349A EE05587B1 (en) 2001-01-25 2002-01-25 A method for making collagen
EA200300821A EA005697B1 (en) 2001-01-25 2002-01-25 A method for preparing a collagen sponge
DK02718481T DK1368419T3 (en) 2001-01-25 2002-01-25 Process for producing a collagen sponge, a device for extracting a portion of a collagen foam and an elongated collagen sponge
NO20033295A NO332462B1 (en) 2001-01-25 2003-07-22 Process for making a collagen sponge.
IL157096A IL157096A (en) 2001-01-25 2003-07-24 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam and an elongated collagen sponge
BG108122A BG66343B1 (en) 2001-01-25 2003-08-21 A method of preparing a collagen sponge
HK04101070A HK1058371A1 (en) 2001-01-25 2004-02-16 A method of preparing a collagen songe, a device for extracting a part of a collagen foam, and an elongated collagen sponge

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200100135 2001-01-25
DKPA200100135 2001-01-25
DKPA200100235 2001-02-13
DKPA200100235 2001-02-13

Publications (3)

Publication Number Publication Date
WO2002070594A2 true WO2002070594A2 (en) 2002-09-12
WO2002070594A3 WO2002070594A3 (en) 2003-01-03
WO2002070594A8 WO2002070594A8 (en) 2004-03-11

Family

ID=26068956

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB2002/001453 WO2002058749A2 (en) 2001-01-25 2002-01-25 Carrier with solid fibrinogen and solid thrombin
PCT/IB2002/001452 WO2002070594A2 (en) 2001-01-25 2002-01-25 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
PCT/IB2002/001454 WO2002058750A2 (en) 2001-01-25 2002-01-25 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001453 WO2002058749A2 (en) 2001-01-25 2002-01-25 Carrier with solid fibrinogen and solid thrombin

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001454 WO2002058750A2 (en) 2001-01-25 2002-01-25 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same

Country Status (37)

Country Link
EP (4) EP1343542B1 (en)
JP (4) JP4535678B2 (en)
KR (2) KR100830294B1 (en)
CN (3) CN1290907C (en)
AR (3) AR032517A1 (en)
AT (2) ATE310044T1 (en)
AU (3) AU2002255220B2 (en)
BG (3) BG66439B1 (en)
BR (3) BRPI0206709B8 (en)
CA (3) CA2434964C (en)
CL (1) CL2015003111A1 (en)
CR (1) CR7034A (en)
CZ (3) CZ304357B6 (en)
DE (2) DE60203364T2 (en)
DK (2) DK1343542T3 (en)
EA (4) EA006686B1 (en)
EE (3) EE05587B1 (en)
EG (2) EG26417A (en)
ES (2) ES2238569T3 (en)
HK (2) HK1058319A1 (en)
HR (1) HRP20030648B1 (en)
HU (3) HU227987B1 (en)
IL (6) IL157097A0 (en)
IS (1) IS6885A (en)
ME (1) ME00587A (en)
MX (3) MXPA03006688A (en)
NO (3) NO332462B1 (en)
NZ (3) NZ527166A (en)
PL (3) PL206197B1 (en)
PT (1) PT1343542E (en)
RS (1) RS50866B (en)
SI (2) SI1343542T1 (en)
SK (3) SK287874B6 (en)
TW (2) TWI237573B (en)
UA (1) UA73028C2 (en)
UY (1) UY27136A1 (en)
WO (3) WO2002058749A2 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092820B2 (en) 2001-07-17 2012-01-10 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
WO2012159635A1 (en) 2011-05-24 2012-11-29 Nycomed Pharma As Rolled collagen carrier
US8357378B2 (en) 1996-08-27 2013-01-22 Baxter International Inc. Fragmented polymeric compositions and methods for their use
WO2013174879A1 (en) 2012-05-24 2013-11-28 Takeda Nycomed As Packaging
WO2013174874A1 (en) 2012-05-24 2013-11-28 Takeda Nycomed As Apparatus and process for providing a coiled collagen carrier
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8703122B2 (en) 2006-05-31 2014-04-22 Baxter International Inc. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US8703170B2 (en) 2010-04-07 2014-04-22 Baxter International Inc. Hemostatic sponge
US8771258B2 (en) 2009-12-16 2014-07-08 Baxter International Inc. Hemostatic sponge
US8790698B2 (en) 2007-10-30 2014-07-29 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US8834864B2 (en) * 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US8940335B2 (en) 2010-06-01 2015-01-27 Baxter International Inc. Process for making dry and stable hemostatic compositions
US8962025B2 (en) 2006-08-02 2015-02-24 Baxter International Inc. Rapidly acting dry sealant and methods for use and manufacture
US9005609B2 (en) 2003-08-07 2015-04-14 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
US9084728B2 (en) 2010-06-01 2015-07-21 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9162006B2 (en) 2009-06-16 2015-10-20 Baxter International Inc. Hemostatic sponge
US9408945B2 (en) 2010-06-01 2016-08-09 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9439999B2 (en) 2011-07-28 2016-09-13 Harbin Peiqilong Biopharmaceutical Co., Ltd Composite collagen sponge and preparation method thereof
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9821025B2 (en) 2011-10-11 2017-11-21 Baxter International Inc. Hemostatic compositions
US9833541B2 (en) 2011-10-27 2017-12-05 Baxter International Inc. Hemostatic compositions
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10322170B2 (en) 2011-10-11 2019-06-18 Baxter International Inc. Hemostatic compositions
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020131933A1 (en) * 1996-01-16 2002-09-19 Yves Delmotte Biopolymer membrane and methods for its preparation
US7279177B2 (en) 2002-06-28 2007-10-09 Ethicon, Inc. Hemostatic wound dressings and methods of making same
US7252837B2 (en) 2002-06-28 2007-08-07 Ethicon, Inc. Hemostatic wound dressing and method of making same
AU2003277833A1 (en) * 2002-11-04 2004-06-07 Nycomed Danmark Aps Coating of a particulate material with an organic solvent-based coating composition
KR101213460B1 (en) 2003-01-20 2012-12-20 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 Hemostatic materials
DE602004025217D1 (en) 2003-04-04 2010-03-11 Tissuemed Ltd
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7186684B2 (en) 2003-08-07 2007-03-06 Ethicon, Inc. Hemostatic device containing a protein precipitate
MX2007001554A (en) 2004-08-03 2007-04-10 Tissuemed Ltd Tissue-adhesive materials.
CN101137402B (en) 2004-10-20 2012-01-11 伊西康公司 Reinforced absorbable multilayered fabric for use in medical devices and its preparation thereof
BRPI0516764B8 (en) * 2004-10-20 2021-05-25 Ethicon Inc hemostat
US9358318B2 (en) 2004-10-20 2016-06-07 Ethicon, Inc. Method of making a reinforced absorbable multilayered hemostatic wound dressing
KR20060040329A (en) * 2004-11-05 2006-05-10 나건 Hemostatic agent which can be applied via endoscope and applying method of the same
ES2427565T3 (en) 2005-04-25 2013-10-31 Massachusetts Institute Of Technology Self-assembling peptides to promote hemostasis
JP4864348B2 (en) * 2005-05-27 2012-02-01 川澄化学工業株式会社 Nerve regeneration tube
CA2640629A1 (en) 2006-02-03 2007-08-09 Tissuemed Limited Tissue-adhesive materials
AU2007215382B2 (en) 2006-02-14 2013-11-14 Commonwealth Scientific And Industrial Research Organisation Joining and/or sealing tissues through photo-activated cross-linking of matrix proteins
EP2012842B1 (en) 2006-04-25 2018-04-04 Massachusetts Institute of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions
WO2008019126A2 (en) * 2006-08-04 2008-02-14 Stb Lifesaving Technologies, Inc. Process for production of solid wound dressing
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
CN101053679B (en) * 2007-04-17 2010-05-26 浙江大学 Method for preparing polymer multiporous holder filled with fiber protein gel
DE102007037056A1 (en) 2007-07-24 2009-01-29 Aesculap Ag Hemostyptic made of freeze-dried collagen, useful e.g. to increase absorption capacity of liquids, preferably blood and treat blood vessel leakage, comprises a water-soluble biocompatible organic acid, preferably hydroxyl carboxylic acid
DE102007037053A1 (en) 2007-07-24 2009-01-29 Aesculap Ag Hemostatic for minimally invasive surgery
DE102007045066A1 (en) 2007-09-20 2009-04-02 Mike Ehrlich Hemostatic material containing synthetic peptides or polysaccharides
DE102007000574A1 (en) 2007-10-25 2009-04-30 FILK Forschungsinstitut für Leder- und Kunstbahnen gGmbH Biologically absorbable sponge material, useful in medicine, pharmacy, cosmetics and food area, comprises a collagen-gelatin-mixture or collagen-gelatin-mixture with additives, preferably softener and/or a substance
CN101214391B (en) * 2007-12-27 2010-05-19 广州倍绣生物技术有限公司 High-efficiency biogum sealant and uses thereof
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
WO2010002435A2 (en) * 2008-07-03 2010-01-07 Kulinets Irina B Hemostatic pouch and method to stabilize hemostatic components
EP3470093B1 (en) 2008-10-06 2020-08-19 3-D Matrix Ltd. Tissue plug
US9271925B2 (en) 2013-03-11 2016-03-01 Bioinspire Technologies, Inc. Multi-layer biodegradable device having adjustable drug release profile
EP2477617B1 (en) 2009-09-18 2018-01-31 Bioinspire Technologies Inc. Free-standing biodegradable patch
WO2011072482A1 (en) 2009-12-14 2011-06-23 The University Of Hong Kong Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells
CA2787883C (en) 2010-01-28 2019-02-19 Erez Ilan Method for improved fibrin sealing
US20130183366A1 (en) * 2010-07-20 2013-07-18 The Chemo-Sero-Therapeutic Research Institute Sheet preparation for tissue adhesion
RU2013155713A (en) * 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
US20130041406A1 (en) * 2011-08-10 2013-02-14 Brian W. Bear Surgical staple with localized adjunct coating
EP2556842A1 (en) 2011-08-11 2013-02-13 Bioftalmik, S.L. Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof
TWI584825B (en) * 2012-05-14 2017-06-01 帝人股份有限公司 Formed sheet product and hemostatic material
EP2869903B1 (en) 2012-07-06 2018-11-28 3-D Matrix Ltd. Fill-finish process for peptide solutions
DE102013004420A1 (en) 2012-08-20 2014-02-20 Alexander Kopp Support body and method for its production
CA2893064C (en) * 2012-12-07 2021-05-04 Baxter International Inc. Hemostatic foam
KR101401944B1 (en) 2012-12-11 2014-05-30 세원셀론텍(주) Tissue sealant of collagen and fibrin mixed and method of manufacturing the same
US10765774B2 (en) 2013-07-09 2020-09-08 Ethicon, Inc. Hemostatic pad assembly kit and method
JP6684719B2 (en) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス Sterilization and filtration of peptide compositions
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
ES2712608T3 (en) 2014-03-10 2019-05-14 3 D Matrix Ltd Self-assembling peptides for the treatment of pulmonary bullae
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
CN106267328B (en) * 2016-09-20 2019-04-12 安徽思维特生物科技有限公司 A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel
CN106730031A (en) * 2016-12-30 2017-05-31 清华大学 A kind of bionic fiber protein hydrogel beam repaired for spinal cord injury and preparation method thereof
EP3723726A1 (en) 2017-12-15 2020-10-21 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses in drug delivery
RU2679616C1 (en) * 2018-07-02 2019-02-12 Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Method for preparing a thrombofibrin clot with growth-stimulating properties
US20220016311A1 (en) * 2018-12-14 2022-01-20 Bmg Incorporated Two-reactant sheet-shaped adhesive/reinforcement for tissues
CN112225937B (en) * 2020-10-14 2022-11-01 中山大学 Temperature-sensitive macroporous biological hydrogel and preparation method and application thereof
CN113117158B (en) * 2021-03-10 2022-07-26 复旦大学 Material for biological functional modification of surface denatured protein and preparation method and application thereof
CN114177346B (en) * 2021-12-24 2023-05-26 中国人民解放军军事科学院军事医学研究院 Hemostatic composition and hemostatic patch and application thereof
CN114246974B (en) * 2021-12-24 2023-11-03 中国人民解放军军事科学院军事医学研究院 Preparation method of hemostatic patch

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292326A (en) * 1968-11-27 1972-10-11 Ct Tech Du Cuir Method and apparatus for the preparation of collagen dispersions with a view to their applications
US4626286A (en) * 1983-10-31 1986-12-02 Schmid Laboratories, Inc. Collagen gel and the process of making said gel
FR2668936A1 (en) * 1990-11-09 1992-05-15 Eberlin Jean Luc Graft based on collagen and fibrin adhesive for osseocartilaginous reconstruction, and method for its preparation
EP0578823A1 (en) * 1991-04-08 1994-01-19 Sumitomo Pharmaceuticals Company, Limited Porous solid preparation containing physiologically active protein substance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3105624A1 (en) * 1981-02-16 1982-09-02 Hormon-Chemie München GmbH, 8000 München MATERIAL FOR SEALING AND HEALING Wounds
BR8102435A (en) * 1981-04-15 1982-11-30 Campos Vidal Benedicto MICROFIBRILLARY AND MICRO CRYSTALLINE COLLAGEN FOR MEDICINE AND PHARMACY APPLICATION
DE3214337C2 (en) * 1982-04-19 1984-04-26 Serapharm - Michael Stroetmann, 4400 Münster Resorbable flat material for sealing and healing wounds and processes for their manufacture
US5318524A (en) * 1990-01-03 1994-06-07 Cryolife, Inc. Fibrin sealant delivery kit
AT410754B (en) * 1993-03-31 2003-07-25 Nycomed Austria Gmbh DEVICE FOR EVENLY APPLYING A SUSPENSION TO A COLLAGE CARRIER
US6177126B1 (en) * 1993-03-31 2001-01-23 Nycomed Arzneimittel Gmbh Process for the production of a material for sealing and healing wounds
JPH0759812A (en) * 1993-08-27 1995-03-07 Koken Co Ltd Wound cover material and its production
CN1159206A (en) * 1994-09-02 1997-09-10 纽约血库公司 Production and secretion of recombinant fibrinogen by yeast
WO1997028832A1 (en) * 1996-02-06 1997-08-14 New Generation Medical Corporation Composition for sealing wounds
HUP9903586A3 (en) * 1996-04-04 2003-02-28 Baxter Ag Hemostatic sponge based on collagen
CA2330972C (en) * 1998-05-01 2008-08-19 Zymogenetics, Inc. Fully recombinant tissue sealant compositions
CA2295609C (en) * 1998-05-19 2009-09-29 The American National Red Cross Hemostatic sandwich bandage
WO2000009018A1 (en) * 1998-08-10 2000-02-24 Fibrogen, Inc. Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
WO2000038752A1 (en) * 1998-12-23 2000-07-06 Aventis Behring Gmbh Fibrin-based glue granulate and corresponding production method
DE19922078A1 (en) * 1999-05-15 2000-11-23 Weitzel Kage Doris Tissue construct for transplant surgery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292326A (en) * 1968-11-27 1972-10-11 Ct Tech Du Cuir Method and apparatus for the preparation of collagen dispersions with a view to their applications
US4626286A (en) * 1983-10-31 1986-12-02 Schmid Laboratories, Inc. Collagen gel and the process of making said gel
FR2668936A1 (en) * 1990-11-09 1992-05-15 Eberlin Jean Luc Graft based on collagen and fibrin adhesive for osseocartilaginous reconstruction, and method for its preparation
EP0578823A1 (en) * 1991-04-08 1994-01-19 Sumitomo Pharmaceuticals Company, Limited Porous solid preparation containing physiologically active protein substance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 98, no. 24, 13 June 1983 (1983-06-13) Columbus, Ohio, US; abstract no. 204391, VIDAL B.C. ET AL.: "Microfibrous and microcrystalline collagen I for use in medicine and pharmacy" XP002170464 cited in the application & BR 8 102 435 A 30 November 1982 (1982-11-30) *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 6, 31 July 1995 (1995-07-31) & JP 07 059812 A (KOKEN CO LTD), 7 March 1995 (1995-03-07) & DATABASE WPI Week 199518 Derwent Publications Ltd., London, GB; AN 1995-135943 *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8357378B2 (en) 1996-08-27 2013-01-22 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8092820B2 (en) 2001-07-17 2012-01-10 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8383141B2 (en) 2001-07-17 2013-02-26 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8834864B2 (en) * 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US9005609B2 (en) 2003-08-07 2015-04-14 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US8703122B2 (en) 2006-05-31 2014-04-22 Baxter International Inc. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US8962025B2 (en) 2006-08-02 2015-02-24 Baxter International Inc. Rapidly acting dry sealant and methods for use and manufacture
US9114172B2 (en) 2006-08-02 2015-08-25 Baxter International Inc. Rapidly acting dry sealant and methods for use and manufacture
US8790698B2 (en) 2007-10-30 2014-07-29 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
US9993298B2 (en) 2009-05-18 2018-06-12 Baxter International Inc. Method for the improvement of mesh implant biocompatibility
US9162006B2 (en) 2009-06-16 2015-10-20 Baxter International Inc. Hemostatic sponge
US11071804B2 (en) 2009-12-16 2021-07-27 Baxter International Inc. Hemostatic sponge
US8771258B2 (en) 2009-12-16 2014-07-08 Baxter International Inc. Hemostatic sponge
US9872934B2 (en) 2009-12-16 2018-01-23 Baxter International Inc. Hemostatic sponge
US9517287B2 (en) 2009-12-16 2016-12-13 Baxter International, Inc. Hemostatic sponge
US8703170B2 (en) 2010-04-07 2014-04-22 Baxter International Inc. Hemostatic sponge
US10441674B2 (en) 2010-04-07 2019-10-15 Baxter International Inc. Hemostatic sponge
US11478566B2 (en) 2010-04-07 2022-10-25 Baxter International Inc. Hemostatic sponge
US9375505B2 (en) 2010-04-07 2016-06-28 Baxter International Inc. Hemostatic sponge
US10245348B2 (en) 2010-06-01 2019-04-02 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9084728B2 (en) 2010-06-01 2015-07-21 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9408945B2 (en) 2010-06-01 2016-08-09 Baxter International Inc. Process for making dry and stable hemostatic compositions
US10994045B2 (en) 2010-06-01 2021-05-04 Baxter International Inc. Process for making dry and stable hemostatic compositions
US8940335B2 (en) 2010-06-01 2015-01-27 Baxter International Inc. Process for making dry and stable hemostatic compositions
WO2012159635A1 (en) 2011-05-24 2012-11-29 Nycomed Pharma As Rolled collagen carrier
US10532032B2 (en) 2011-05-24 2020-01-14 Takeda As Rolled collagen carrier
MD4471C1 (en) * 2011-05-24 2017-10-31 Takeda As Rolled collagen carrier
US9814686B2 (en) 2011-05-24 2017-11-14 Takeda As Rolled collagen carrier
EP3243489A1 (en) 2011-05-24 2017-11-15 Takeda AS Rolled collagen carrier
US9439999B2 (en) 2011-07-28 2016-09-13 Harbin Peiqilong Biopharmaceutical Co., Ltd Composite collagen sponge and preparation method thereof
US9821025B2 (en) 2011-10-11 2017-11-21 Baxter International Inc. Hemostatic compositions
US10322170B2 (en) 2011-10-11 2019-06-18 Baxter International Inc. Hemostatic compositions
US9833541B2 (en) 2011-10-27 2017-12-05 Baxter International Inc. Hemostatic compositions
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
CN104470475B (en) * 2012-05-24 2017-04-19 武田有限公司 Apparatus and process for providing a coiled collagen carrier
WO2013174879A1 (en) 2012-05-24 2013-11-28 Takeda Nycomed As Packaging
WO2013174874A1 (en) 2012-05-24 2013-11-28 Takeda Nycomed As Apparatus and process for providing a coiled collagen carrier
US10485715B2 (en) 2012-05-24 2019-11-26 Takeda As Packaging for form-stable coiled collagen carrier
CN104470475A (en) * 2012-05-24 2015-03-25 武田奈科明有限公司 Apparatus and process for providing a coiled collagen carrier
US10213345B2 (en) 2012-05-24 2019-02-26 Takeda As Apparatus and process for providing a coiled collagen carrier
RU2614324C2 (en) * 2012-05-24 2017-03-24 Такеда Ас Packaging
US11000985B2 (en) 2012-05-24 2021-05-11 Takeda As Apparatus and process for providing a coiled collagen carrier
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10799611B2 (en) 2012-06-12 2020-10-13 Ferrosan Medical Devices A/S Dry haemostatic composition
US10595837B2 (en) 2013-06-21 2020-03-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US11103616B2 (en) 2013-12-11 2021-08-31 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Also Published As

Publication number Publication date
HUP0303896A2 (en) 2004-03-01
EP1547626A2 (en) 2005-06-29
PL363274A1 (en) 2004-11-15
DE60203364D1 (en) 2005-04-28
BRPI0206708B1 (en) 2015-07-14
HUP0303893A3 (en) 2012-02-28
CA2434964A1 (en) 2002-08-01
EE200300341A (en) 2003-10-15
BG66343B1 (en) 2013-07-31
IS6885A (en) 2003-07-24
EA006686B1 (en) 2006-02-24
ME00587B (en) 2011-12-20
MXPA03006687A (en) 2004-03-12
AR032517A1 (en) 2003-11-12
AU2002255220B2 (en) 2007-05-31
JP2004521115A (en) 2004-07-15
EA200300821A1 (en) 2004-04-29
IL157097A (en) 2009-12-24
KR100847417B1 (en) 2008-07-18
IL157095A (en) 2009-06-15
ATE291445T1 (en) 2005-04-15
IL157096A0 (en) 2004-02-08
KR100830294B1 (en) 2008-05-16
AR032400A1 (en) 2003-11-05
EA200300822A1 (en) 2004-02-26
EA006540B1 (en) 2006-02-24
KR20030085522A (en) 2003-11-05
EE05685B1 (en) 2013-12-16
DK1343542T3 (en) 2005-07-25
JP2004520124A (en) 2004-07-08
CN1507358A (en) 2004-06-23
CZ20032199A3 (en) 2003-12-17
IL157097A0 (en) 2004-02-08
CR7034A (en) 2004-03-05
UA73028C2 (en) 2005-05-16
NZ527165A (en) 2005-02-25
NO20033297L (en) 2003-09-25
NO20033297D0 (en) 2003-07-22
WO2002058750A8 (en) 2004-03-11
EP1368419A2 (en) 2003-12-10
CA2435425C (en) 2010-07-27
JP2005502733A (en) 2005-01-27
HUP0400768A3 (en) 2006-01-30
DE60207389D1 (en) 2005-12-22
CN1487967A (en) 2004-04-07
NO20033296D0 (en) 2003-07-22
NO20033296L (en) 2003-09-25
CZ20032197A3 (en) 2003-11-12
NO332462B1 (en) 2012-09-24
UY27136A1 (en) 2002-09-30
EG26417A (en) 2013-10-22
EP1343542A2 (en) 2003-09-17
BR0206708A (en) 2004-02-25
YU67003A (en) 2006-05-25
NO20033295D0 (en) 2003-07-22
HK1058319A1 (en) 2004-05-14
EE05587B1 (en) 2012-10-15
HUP0400768A2 (en) 2004-07-28
KR20030086254A (en) 2003-11-07
DE60207389T2 (en) 2006-08-03
WO2002058749A8 (en) 2004-03-11
BRPI0206705B8 (en) 2021-07-27
BG108122A (en) 2004-09-30
CN1246047C (en) 2006-03-22
MXPA03006688A (en) 2004-03-12
PL366932A1 (en) 2005-02-07
BR0206709A (en) 2004-02-17
CZ20032198A3 (en) 2003-12-17
CN1264578C (en) 2006-07-19
CA2434964C (en) 2009-04-21
SK288120B6 (en) 2013-09-03
JP2007190399A (en) 2007-08-02
SI1343542T1 (en) 2005-10-31
BG66439B1 (en) 2014-08-29
CA2435425A1 (en) 2002-08-01
BG66420B1 (en) 2014-03-31
PL206197B1 (en) 2010-07-30
SI1368419T1 (en) 2006-06-30
NO327386B1 (en) 2009-06-22
EG24589A (en) 2009-12-01
BG108121A (en) 2004-08-31
WO2002058750A2 (en) 2002-08-01
EP1547626A3 (en) 2009-07-29
HU228810B1 (en) 2013-05-28
SK10362003A3 (en) 2004-03-02
CN1290907C (en) 2006-12-20
PL363275A1 (en) 2004-11-15
WO2002058749A2 (en) 2002-08-01
PT1343542E (en) 2005-08-31
BR0206705A (en) 2004-02-25
JP4104462B2 (en) 2008-06-18
ATE310044T1 (en) 2005-12-15
HUP0303893A2 (en) 2004-03-01
NZ527166A (en) 2005-03-24
ES2253523T3 (en) 2006-06-01
RS50866B (en) 2010-08-31
WO2002070594A3 (en) 2003-01-03
HRP20030648A2 (en) 2005-06-30
BRPI0206708B8 (en) 2021-06-22
WO2002070594A8 (en) 2004-03-11
SK287874B6 (en) 2012-02-03
CA2435159C (en) 2009-07-28
EE200300349A (en) 2003-10-15
EA005697B1 (en) 2005-04-28
WO2002058750A3 (en) 2002-10-31
WO2002058749A3 (en) 2002-10-10
HU227987B1 (en) 2012-07-30
BRPI0206709B1 (en) 2015-09-08
HRP20030648B1 (en) 2011-10-31
AR032800A1 (en) 2003-11-26
EA006700B1 (en) 2006-02-24
IL157096A (en) 2007-08-19
EA200401463A1 (en) 2005-08-25
EP1368419B1 (en) 2005-11-16
BG108123A (en) 2004-09-30
ES2238569T3 (en) 2005-09-01
CN1487843A (en) 2004-04-07
SK10352003A3 (en) 2004-02-03
EA200300823A1 (en) 2004-04-29
NO20033295L (en) 2003-09-25
EP1359947A2 (en) 2003-11-12
HK1058371A1 (en) 2004-05-14
TWI255726B (en) 2006-06-01
ME00587A (en) 2011-12-20
SK10342003A3 (en) 2004-02-03
CA2435159A1 (en) 2002-09-12
CZ304357B6 (en) 2014-03-26
PL205181B1 (en) 2010-03-31
CL2015003111A1 (en) 2016-07-08
EE200300348A (en) 2003-10-15
BR0206705B1 (en) 2012-08-07
IL157095A0 (en) 2004-02-08
DE60203364T2 (en) 2005-09-01
EP1343542B1 (en) 2005-03-23
NZ527167A (en) 2005-02-25
BRPI0206709B8 (en) 2021-06-22
HUP0303896A3 (en) 2005-12-28
JP4535678B2 (en) 2010-09-01
TWI237573B (en) 2005-08-11
MXPA03006689A (en) 2004-03-12
CZ305120B6 (en) 2015-05-13
PL206194B1 (en) 2010-07-30
EE05678B1 (en) 2013-10-15
AU2002307809B2 (en) 2007-10-04
DK1368419T3 (en) 2006-04-03
AU2002249528B2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
EP1368419B1 (en) A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
US7098315B2 (en) Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
AU2002249528A1 (en) A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge
EP1259269B1 (en) Agent for the treatment of wounds
US20120294823A1 (en) Method for preparing silk sericin-PVA scaffold using genipin as crosslinking agent
WO1999064655A1 (en) Collagen material and process for producing the same
EP3122300A1 (en) A ready to use biodegradable and biocompatible device and a method of preparation thereof
WO1989008465A1 (en) Medical material permitting cells to enter thereinto and artificial skin
CN110639050A (en) Silk fibroin nanofiber and preparation method of silver-loaded antibacterial dressing based on silk fibroin nanofiber
EP0042253B1 (en) Fibrous collagenous hemostatic-adhesive web and method for its preparation
Silverstein et al. Collagen fibers as a fleece hemostatic agent
JP2000060956A (en) Collagen material and manufacture thereof
WO2001066159A1 (en) Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such
US5138030A (en) Process for extracting type I collagen form an avian source, and applications therefor
ZA200305591B (en) A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge.
EP1325060B1 (en) Soybean-based thermoplastics as biomaterials
CN115227878B (en) Silver-loaded type-I collagen composite material and preparation method and application thereof
Koller et al. Biocompatibility studies of modified collagen/Hyaluronan membranes after implantation
CN117547657A (en) Biological adhesive film and preparation method thereof
JP2016501270A (en) Collagen powder

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2435159

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/05591

Country of ref document: ZA

Ref document number: 200305591

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002249528

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 157096

Country of ref document: IL

Ref document number: 527166

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006687

Country of ref document: MX

Ref document number: 2002570628

Country of ref document: JP

Ref document number: 028040953

Country of ref document: CN

Ref document number: 1020037009893

Country of ref document: KR

Ref document number: 01165/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002718481

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2003-2198

Country of ref document: CZ

Ref document number: 10362003

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 10812202

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200300821

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020037009893

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002718481

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-2198

Country of ref document: CZ

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 37/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWP Wipo information: published in national office

Ref document number: 527166

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 527166

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002718481

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002249528

Country of ref document: AU